Shucai Zhang

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4K citations

Medicine, Pathology, Bronchial Neoplasm +8

Source diagnostics of polycyclic aromatic hydrocarbons in urban road runoff, dust, rain and canopy throughfall

Wei Zhang, Shucai Zhang, Chao Wan et al. · Environmental Pollution · 2008 · 334 citations

Environmental Chemistry, Chemical Emission, Environmental Monitoring +10

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Li Zhang, Shenglin Ma, Xiangqun Song et al. · The Lancet Oncology · 2012 · 225 citations

Medicine, Clinical Trials, Maintenance Therapy +9

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 211 citations

Versus Gefitinib, Medicine, Pathology +8

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Yuankai Shi, Junling Li, Shucai Zhang et al. · PLoS ONE · 2015 · 200 citations · Full text